toggle visibility Search & Display Options

Select All    Deselect All
 |   | 
Details
   print
  Record Links
Author (up) Kueppers, F.; Sanders, C. url  doi
openurl 
  Title State-of-the-art testing for alpha-1 antitrypsin deficiency Type Journal Article
  Year 2017 Publication Allergy and Asthma Proceedings Abbreviated Journal Allergy Asthma Proc  
  Volume 38 Issue 2 Pages 108-114  
  Keywords Asthma/diagnosis; Diagnosis, Differential; Genetic Testing/economics/*methods; Genotype; Genotyping Techniques; High-Throughput Nucleotide Sequencing/economics/*methods; Humans; Sequence Analysis, DNA/economics/methods; alpha 1-Antitrypsin/blood/*genetics; alpha 1-Antitrypsin Deficiency/blood/*diagnosis/genetics  
  Abstract BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) is a genetic condition characterized by low serum levels of the protein alpha-1 antitrypsin. Because there are no unique clinical symptoms that point to a definitive diagnosis of AATD, laboratory testing is crucial to differentiate this disease from others. OBJECTIVE: To summarize advances in laboratory techniques used to test for AATD. METHODS: Data were sourced from a nonsystematic literature review of MEDLINE and the author's personal literature collection, and by checking reference lists of sourced articles. RESULTS: Since the original description of AATD by Laurell and Eriksson in 1963, testing methods have undergone major changes. Currently, alpha-1 antitrypsin protein is quantified by immunologic measurement in serum, and the phenotype is characterized by isoelectric focusing and/or targeted genotyping of predefined mutations. In addition, whole-gene sequencing of the gene SERPINA1 can be undertaken. However, this is costly and generally used only if targeted genotyping cannot conclusively identify the variant. The introduction of next-generation sequencing (NGS), which enables rapid and accurate sequencing of large quantities of DNA fragments in a single reaction, may help reduce costs. With its increasing availability, NGS may begin to appear in testing protocols. Clinical guidelines recommend that patients are tested for AATD if they have chronic irreversible airflow obstruction, especially those with early onset disease or a positive family history of AATD. Despite this, AATD is still underrecognized, and significant delays exist between symptom onset and diagnosis. CONCLUSION: Traditional testing practices have limitations. Screening programs that incorporate NGS are the most comprehensive methods available for accurate diagnosis of AATD.  
  Address  
  Corporate Author Thesis  
  Publisher Place of Publication Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Edition  
  ISSN 1088-5412 ISBN Medium  
  Area Expedition Conference  
  Notes PMID:28120746 Approved no  
  Call Number refbase @ user @ Serial 17101  
Permanent link to this record
Select All    Deselect All
 |   | 
Details
   print

Save Citations:
Export Records: